The US Food and Drug Administration (FDA) has granted approval to Valneva's single-shot vaccine, Ixchiq.
Now, this can be used for the prevention of chikungunya virus in adults aged 18 and older.
This marks a major milestone as the first preventive shot approved in the United States for adults suffering from chikungunya, a mosquito-borne disease.
Chikungunya virus is primarily transmitted to humans through the bite of infected mosquitoes.
At least 5 million cases reported in the past 15 years.